Tab. 2.

SLS models for all 4 groups. Layout as Tab. 1.

SLS MODEL PEAK VELOCITY [eq. 1] (n=60)
Group	CPKV Average	CPKV ±SD	CPKV Range	CPKV >0/<0/~0	t-value	Prob	R2 Average	R2 ±SD	R2 Range
Placebo	−0.003	0.027	−0.094 0.054	13/16/31	−0.9	0.4	0.76	0.13	0.33 0.97
Propof.	−0.038*	0.033	−0.117 0.018	1/50/9	−8.7	3×10−12	0.69	0.19	0.23 0.94
Midaz.	−0.035*	0.036	−0.191 0.073	0/51/9	−7.5	4×10−10	0.66	0.18	0.25 0.92
Dexmed.	−0.020*	0.027	−0.095 0.024	4/35/21	−5.7	4×10−7	0.69	0.16	0.19 0.95

SLS MODEL DURATION [eq. 2] (n=60)
Group	CDUR Average	CDUR ±SD	CDUR Range	CDUR >0/<0/~0	t-value	Prob	R2 Average	R2 ±SD	R2 Range
Placebo	0.008	0.037	−0.047 0.150	22/14/24	1.7	0.09	0.63	0.27	0.05 0.98
Propof.	0.157*	0.298	−0.037 1.741	44/2/14	4.1	1×10−4	0.43	0.27	0.03 0.89
Midaz.	0.143*	0.159	−0.017 0.887	55/0/5	7.0	3×10−9	0.39	0.20	0.07 0.82
Dexmed.	0.108*	0.153	−0.062 0.752	42/1/17	5.5	1×10−6	0.44	0.20	0.04 0.86

SLS MODEL RECIPROCAL OF LATENCY [eq. 3] (n=60)
Group	CRLAT Average	CRLAT ±SD	CRLAT Range	CRLAT >0/<0/~0	t-value	Prob	R2 Average	R2 ±SD	R2 Range
Placebo	0.019*	0.043	−0.123 0.197	32/5/23	3.5	0.001	0.13	0.10	0.01 0.39
Propof.	−0.025*	0.025	−0.086 0.022	4/40/16	−7.8	1×10−10	0.17	0.12	0.01 0.57
Midaz.	−0.022*	0.016	−0.070 0.026	1/47/12	−10.3	9×10−15	0.15	0.10	0.00 0.39
Dexmed.	−0.008*	0.021	−0.071 0.032	12/23/25	−2.9	0.006	0.12	0.09	0.01 0.39

SLS MODEL GAIN PRIMARY SACCADE [eq. 4] (n=60)
Group	CGAIN Average	CGAIN ±SD	CGAIN Range	CGAIN >0/<0/~0	t-value	Prob	R2 Average	R2 ±SD	R2 Range
Placebo	0.004*	0.013	−0.026 0.031	24/11/25	2.5	0.014	0.21	0.15	0.00 0.61
Propof.	−0.014*	0.021	−0.096 0.029	5/34/21	−5.3	2×10−6	0.17	0.13	0.00 0.49
Midaz.	−0.025*	0.025	−0.153 0.015	2/49/9	−7.9	9×10−11	0.25	0.15	0.01 0.63
Dexmed.	0.001	0.021	−0.075 0.073	14/17/29	0.5	0.6	0.17	0.13	0.01 0.54